Last week, the FAST-Forward Boost trial completed recruitment to the Early Side Effects Substudy with 345 patients randomised.
The study will now be transitioning to the main trial part of the study with a target of 4,830 patients.
You can read more about the trial here: www.icr.ac.uk/ff-boost
We support #WorldRTDay and the multiprofession approach to high quality #clinicaltrials leading to improved treatment and outcomes for our patients #WRAD
Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring!
Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding:
www.enherts-tr.nhs.uk/careers/vaca...
Deadline 18th August.
DM for further information. #medphys #rtt #rtqa
Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring!
Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding:
www.enherts-tr.nhs.uk/careers/vaca...
Deadline 18th August.
DM for further information. #medphys #rtt #rtqa
We are looking for two exceptional consultant uro-oncologists to come and join our team in Sutton. Please see further details 👇
www.royalmarsden.nhs.uk/current-vaca...
Want to be part of shaping the future direction of RT research in the UK? An exciting opportunity has arisen to work as a research fellow within the @nihr.bsky.social RTTQA Group, based at Mount Vernon Cancer Centre.
For more info please DM us! #radonc #rtqa
www.nhsjobs.com/job/UK/Hertf...
Very excited to do the #RTQA for this trial
Proud to have contributed to this important study #RTQA
Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!
Congratulations Liz on your interdisciplinary award👏🏽🥳 @rttqa.bsky.social _UK does an incredible job ensuring that #radiotherapy is robust. Fantastic leadership! @nhsengland.bsky.social #ESTRO25
Tightenining dose-volume constraints in oesophageal cancer to ensure best practice and further reduce toxicities. Geraint Lewis (Velindre Cancer Centre and @rttqa.bsky.social) presents modified #SCOPE2 trial constraints incorporated into the #PROTIEUS photon vs proton #clinicaltrial
Dr Murray Brunt presents the excellent 10y results of the FAST-FORWARD #breast cancer trial. A pleasure to have contributed to this practice-changing #clinicaltrial
@nihr.bsky.social @icr-ctsu.bsky.social
Rita Simoes presents initial results for deriving dose-volume constraints of the treatment “corridor” in the treatment of limb #sarcoma; with Aisha Miah, Beatrice Seddon and Martin Robinson. UCL CTC and Birmingham CTU #ESTRO25
@pattydiezh.bsky.social @icr-ctsu.bsky.social @yattsang.bsky.social
Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres
www.sciencedirect.com/science/arti...
#NOTCH2025
✅ Quality Assurance is key in clinical trials, yet often overlooked! Dr. Sarah Gwynne SW Wales Cancer Centre (@rttqa.bsky.social) delivered an outstanding session on RT QA in the SCOPE trial
A fantastic deep dive into an essential aspect of oncology research 🎯
Congrats Dr Tree! Proud to have supported the study.
TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy.
www.sciencedirect.com/science/arti...